SCHEMBL7149250

SCHEMBL7149250

COc1ccc2nc(SCS(=O)(=O)Nc3ccc(C)cc3)sc2c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.52
LMNA P02545 6/20 0.52
TP53 P04637 4/20 0.52
MAPT P10636 13/20 0.52
RXFP1 Q9HBX9 2/20 0.50
THRB P10828 2/20 0.48
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
POLB P06746 1/20 0.45
CTSL P07711 1/20 0.45
CTSB P07858 1/20 0.45
CTSK P43235 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151274 0.95 PDK1 (0.55) PDK1LMNATP53MAPTRXFP1
SCHEMBL7149325 0.90 MAPT (0.53) PDK1LMNATP53MAPTRXFP1
SCHEMBL7149774 0.89 MAPT (0.50) PDK1LMNATP53MAPTTHRB
SCHEMBL7150971 0.88 MAPT (0.52) PDK1LMNATP53MAPTRXFP1
SCHEMBL7148785 0.87 MAPT (0.47) LMNATP53MAPTRXFP1MAPK1
SCHEMBL7149256 0.87 MAPT (0.54) PDK1LMNATP53MAPTTHRB
SCHEMBL7151099 0.87 MAPT (0.51) PDK1LMNATP53MAPTRXFP1
SCHEMBL7153222 0.84 PDK1 (0.53) PDK1LMNATP53MAPTRXFP1
SCHEMBL7154367 0.84 L3MBTL1 (0.55) LMNATP53MAPTMAPK1L3MBTL1
SCHEMBL7149643 0.83 PDK1 (0.50) PDK1LMNATP53MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 PDK1 4188/4885LMNA 1481/4885TP53 4600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.